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Background and Purpose: Pegboard tests of hand dexterity are commonly used in clinical 
settings to assess upper extremity function in various populations. For individuals with Parkinson 
disease (PD) the clinical utility of pegboard tests has not been fully evaluated. Our purpose was to 
examine the commercially available 9-Hole Peg Test (9HPT) using a large sample of individuals 
with PD to determine average values, test-retest reliability, and factors predictive of 9HPT 
performance. Methods: 262 individuals with PD (67% male, H&Y = 2.3 +/- 0.7) completed the 
9HPT along with a battery of other tests that included the Movement Disorder Society Unified PD 
Rating Scale - Motor Subscale III and Freezing of Gait Questionnaire.  Results: Average time to 
complete the 9HPT was 31.4 +/- 15.7s with the dominant and 32.2 +/- 12.4s with the non-dominant 
hand. Test-retest reliability of two trials performed with the same hand was high (dominant r = 0.88, 
non-dominant r = 0.91). Women performed the test significantly faster than men, and non-freezers 
significantly faster than freezers. For either hand, age, bradykinesia, and freezing of gait scores 
individually predicted significant portions of the variance in 9HPT time. Gender also was a 
significant predictor, but for the non-dominant hand only. Tremor and rigidity did not predict 
performance. Discussion and Conclusions: The 9HPT appears to be a clinically useful measure 
for assessing upper extremity function in individuals with PD and has advantages over previously 
used methods including standardization, known normative values for healthy controls, commercial 
availability, transportability, and ease of administration.  
 
Key Words: nine hole peg test, Parkinson disease, dexterity 
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BACKGROUND AND PURPOSE 
The motor symptoms of Parkinson disease (PD) commonly affect the upper extremities 
[1-3].  Impaired upper extremity function in PD has been associated with limitations in activities 
of daily living and reductions in quality of life [4]. Although the Unified Parkinson’s Disease 
Rating Scale (UPDRS), the gold standard tool for classifying PD severity and progression, 
assesses upper extremity function in several areas, it is time-consuming, subjective, and has 
suboptimal sensitivity [5]. In addition, items used to assess upper extremity function within the 
UPDRS may not reflect clinically relevant dexterity tasks and as such are not ecologically valid.  
Other measures that might detect subtle impairment or are more responsive to change have 
undergone only limited scrutiny [6-8].  
Several studies have used some version of peg insertion to assess motor function.  For 
example, a series of studies conducted by Müller et al. examined upper extremity function using 
a peg insertion task that involved placement of 25 pegs into a computerized contact board [9-
11].  The authors noted that peg insertion was sensitive to levodopa and other medications and 
related to performance on other motor tests.  More recent work has utilized an 8-peg test where 
pegs were transferred from one row to another [5,12]. The authors of these studies noted that 
the peg insertion task correlated well with disease severity and duration, was quite sensitive for 
discriminating between people with PD and healthy controls and was more sensitive than other 
timed tests designed to assess upper extremity function in PD. They further noted that peg tests 
might be particularly useful, because they require precise coordinated finger movements and do 
not rely heavily on more proximal or axial movements that could be used to compensate for 
deficits in fine motor dexterity.  As such, they suggest that the peg test may be a particularly 
useful tool for screening and also have potential utility as an outcome measure in clinical trials. 
A limitation of these prior studies utilizing peg insertion tasks is that they used 
computerized and/or customized versions of the tests that appear to be specific to that research 
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group.  In contrast, the 9-hole peg test (9HPT) is a commercially available, standardized, well-
established and reliable measure of hand function for healthy adults, with known normative 
values across a broad range of ages [13-15]. The 9HPT requires participants to quickly place 9 
small pegs from a holding tray into holes on a board and then remove them. As such, the 9HPT 
has the potential to serve as an easily administered and useful tool for the assessment of upper 
extremity function in a variety of populations including individuals with neurological conditions 
[17,18].  
To our knowledge, only a few studies have specifically evaluated the 9HPT in people 
with PD [6,19,20].  In one study, a small sample of people with PD performed the 9HPT as part 
of a battery of assessments administered via the internet [19].  This study showed that the 
9HPT could be successfully administered remotely with high intra- and inter-rater reliability.  
Another study utilized the 9HPT as an outcome measure in a study of home exercises and 
noted improvements in 9HPT performance in the exercise group [20].  The results of these 
studies were limited by small sample sizes, and factors that might have contributed to 9HPT 
performance were not evaluated. Thus, the relative influences on 9HPT performance of 
bradykinesia, tremor, and rigidity, as well as sudden arrests in ongoing movement (i.e., motor 
blocks), remain unclear [21,22].  
The broad objective of the present study was to continue to evaluate the potential clinical 
utility of the 9HPT. Specifically, we examined 9HPT results collected from a large sample of 
individuals with PD to determine population-specific average values (and compare these to 
published norms for healthy controls), test-retest reliability, minimal detectable change values, 
and to identify factors predictive of test performance. We also sought to compare 9HPT values 





Two hundred sixty-four individuals with idiopathic PD were recruited and tested at four 
different clinical sites as part of the CHOP_PD study, a prospective longitudinal cohort study 
designed to track the natural history of mobility and quality of life changes in PD [23].  Inclusion 
criteria were as follows:  1) at least 40 years of age, 2) neurologist diagnosed idiopathic PD 
(using UK Brain Bank criteria), 3) Hoehn & Yahr stages 1-4, 4) MMSE > 24/30, and 5) living in 
the community.  Exclusion criteria included diagnosis of atypical Parkinsonism, Hoehn & Yahr 
stage 5, and previous surgical management of PD.  Participants were tested on medication, 
generally 1-1.5 hours after taking their anti-parkinson medication.   
 
Data Collection  
  Complete data collection procedures for the longitudinal study have been described 
elsewhere [23].  The study protocol was approved by the local institutional review boards of 
each of the data collection sites and written informed consent was obtained from all participants 
prior to participation.  Motor impairments were rated by an examiner using the MDS-UPDRS-III 
motor subscale [24].  The occurrence of motor blocks during functional activities was captured 
using a Freezing of Gait questionnaire (FOG-Q) [25].  Participants performed two trials of the 
9HPT with the dominant hand and two with the non-dominant hand.  Dominance was based on 
handedness regardless of which side had more severe PD motor symptoms.  Side of worst 
motor symptoms was well-distributed in the sample and as such was not taken into account in 
the analyses.  Trials were performed first with the dominant hand and then with the non-
dominant hand, per the standardized administration instructions for the test. Trials were 
completed one after the other with a brief rest in between trials.  This short test-retest interval 
was chosen for practical purposes, as we needed to complete the protocol in a single visit.  This 
also allowed us to be sure that medication status was similar across all trials.  Instructions were 
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as follows, “On this test, I want you to pick up the pegs one at a time, using one hand only, and 
put them into the holes as quickly as you can in any order until all the holes are filled.  Then, 
without pausing, remove the pegs one at a time and return them to the container as quickly as 
you can.  We’ll have you do this two times with each hand.  We’ll start with your [DOMINANT] 
hand.  You can hold the peg board steady with your [NON-DOMINANT] hand.  If a peg falls onto 
the table, please retrieve it and continue with the task. If a peg falls on the floor, keep working 
on the task and I will retrieve it for you.  See how fast you can put all of the pegs in and take 
them out again.  Are you ready?  Begin.” 
 
Data Analysis 
Only baseline data were used for analysis. Based on our understanding of upper 
extremity function in PD, variables of interest were: 1) age; 2) gender; 3) medication, expressed 
as daily levodopa equivalents (LEDD); 4) years with diagnosed PD; 5) Hoehn & Yahr (H&Y) 
stage; 6) total score on the FOG_Q; 7) rigidity, operationalized as the MDS-UPDRS score for 
the upper extremity; 8) bradykinesia, operationalized as the sum of MDS-UPDRS finger tapping, 
hand movements, and pronation-supination items for the upper extremity; 9) tremor, 
operationalized as the sum of MDS-UPDRS postural, kinetic, and resting tremor items for the 
upper extremity; and 10) 9HPT scores.  Rigidity, bradykinesia, and tremor scores were 
determined separately for the dominant and non-dominant hand, as were 9HPT scores. 
Descriptive statistics were used to characterize average 9HPT values. Test-retest 
reliability of two trials performed with the same hand was determined using intraclass 
correlations coefficient (ICC 2,1). Minimum detectable change values were calculated using the 
following equation: 
MDCSEM=SD√2(1-rxx) 
where SD is the standard deviation of baseline scores and rxx was the Pearson correlation 
between the two trials performed with the same hand [26]. 
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Values for the two trials performed with the same hand were averaged for all other 
analyses. Performance between men and women, between “freezers” and “non-freezers,” and 
between the study sample and published norms for age-matched healthy controls (n=14 males, 
31 females) [16] were compared using independent samples t-tests on means and standard 
deviations. “Freezers” were defined as individuals with a score of 2 or greater on item 3 of the 
FOG-Q, indicating a history of freezing at least once per week [27]. Pearson correlations were 
used to examine relationships between all measures of interest. Correlations were then used to 
determine which items to enter into multiple regression analyses to determine what factors 
made a significant contribution to explaining 9-HPT performance.  All items that were 
significantly correlated (p ≤ 0.05) were entered into the regression analysis.  Separate multiple 
regression analyses were conducted for each dependent variable for the dominant and non-
dominant hand.  Variance inflation factors were evaluated to ensure that multicollinearity was 
not a concern.  The level of significance for all analyses was set at p < 0.05. 
 
RESULTS 
The final analysis included complete data sets from 262 participants. Study variables 
appear in Table 1 for the sample as a whole, for men vs. women, and for freezers vs. non-
freezers.  For the entire sample, time (mean +/- SD) to complete the 9HPT was 31.4 +/- 15.7s 
with the dominant hand and 32.2 +/- 12.4s with the non-dominant hand. 9HPT times were 
generally lower (i.e., faster speed) among participants at H&Y Stage I (n = 12, dominant = 23.5 
± 5.6s, non-dominant = 23.5 ± 5.2s) relative to participants at H&Y Stage IV (n = 15, dominant = 
43.3 ± 15.9s, non-dominant = 47.9 ± 15.9s) (Table 2). Figure 1 shows 9HPT times for the 
dominant and non-dominant hand in groups of healthy, age-matched men and women control,16 
men and women with PD, and for freezers and non-freezers with PD.  Freezers took longer to 
complete the 9HPT than non-freezers [t(260)= -5.54, p<0.001, 2-tailed].  For people with PD, 
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there were no differences in performance with the dominant versus the non-dominant hand for 
the sample as a whole or for any subgroup. There were no order effects evident in the data. 
Men with PD completed the test in 33.2 ± 14.7s (dominant hand) and 34.4 ± 12.8s (non-
dominant hand), compared to women with PD, who completed the test in 29.1 ± 16.7s 
(dominant hand) and 29.5 ± 11.2s (non-dominant hand). Men with PD took longer to complete 
the 9HPT than women with PD [t(260)= 2.12, p=0.04, 2-tailed].  Compared to age-matched 
controls, men and women with PD took longer to perform the 9HPT with the dominant hand 
[Men: t(161)=-3.04, p=0.003; Women:  t(142)=-3.05, p=0.003] and with the non-dominant hand 
[Men: t(161)=-3.51, p<0.001; Women: t(142)=-3.95, p<0.001].  Age-matched healthy men 
completed the test in 21.1 ± 3.3s (dominant hand) and 22.3 +/- 3.7s (non-dominant hand).  Age-
matched healthy women completed the test in 19.9 ± 3.2s with the dominant hand and 21.4 ± 
3.9s with the non-dominant hand.[16] On average, people with PD took approximately 50% 
longer than healthy adults to complete the test, or on the order of 3 standard deviations above 
the mean of the age-matched healthy adult group.  
Test-retest reliability in the PD sample was high (ICC(2,1) = 0.88 for dominant and 0.91 
for non-dominant) for two consecutive trials using either hand.  The SEM was 1.02s for the 
dominant hand and 0.82s for the non-dominant hand, with a minimum detectable change of 2.6 
s for the dominant hand and 1.3s for the non-dominant hand. 
 
[INSERT TABLE 1 ABOUT HERE] 
[INSERT TABLE 2 ABOUT HERE] 
 
 [INSERT FIGURE 1 ABOUT HERE] 
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Pearson correlations between study variables are shown in Table 3. For each hand, the 
variables that were significant (p ≤ 0.05) were entered into multiple regression analyses.  The 
variables entered were: age, gender, years with PD, H&Y, FOG_Q, rigidity, bradykinesia, and 
tremor. For the dominant hand, age, bradykinesia, and FOG_Q together predicted 29.0% of the 
variance in 9HPT performance, with 21% of the variance explained by bradykinesia alone. For 
the non-dominant hand, age, bradykinesia, FOG_Q, and gender combined to explain 41.0% of 
the variance in 9HPT performance, with gender contributing only 2% to the overall R2; 22% of 
the variance was explained by bradykinesia alone (Table 4). Multicollinearity was not a concern 
in either regression analysis; variance inflation factors were all ≤ 1.2. 
[INSERT TABLE 3 ABOUT HERE] 
 
[INSERT TABLE 4 ABOUT HERE] 
 
DISCUSSION 
The 9HPT is an easily administered, commercially available, “low-tech” clinical 
assessment of upper extremity function, with established normative values for healthy controls 
across a wide range of ages. Previous studies of the 9HPT in people with PD, although 
conducted using small samples, supported its intra- and inter-rater reliability and potential utility 
as a responsive measure of change [19,20]. To our knowledge, the present study is the first to 
generate 9HPT average values, consider test-retest reliability, calculate preliminary MDC 
values, and identify factors that contribute to 9HPT performance specifically for people with PD.   
Test-retest reliability 
Test-retest reliability for two test trials conducted with either hand was high (ICC (2,1) 
=0.88, 0.91), producing relatively small SEM values.  Consequently, the MDC in 9HPT 
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performance in people with PD, H&Y Stages I – IV, was determined to be 2.6s for the dominant 
hand and 1.3s for the non-dominant hand.  The finding suggests that the 9HPT may be a 
relatively sensitive measure of performance changes resulting from disease progression, 
pharmacological intervention, or rehabilitation. Importantly, test-retest reliability of the 9HPT in 
the PD sample was much higher than has been noted previously for healthy controls.  Reasons 
for this discrepancy likely related to differences in the time interval between test administrations.  
In the present study we determined test-retest reliability between trials administered 
consecutively during the same session.  In contrast, prior studies reporting relatively poor test-
retest reliability (r=0.45) compared trials administered one week apart.[15]  Future work should 
determine the test-retest reliability of the 9HPT administered to people with PD in separate 
sessions a week or more apart.   
 
Influence of Non-modifiable Factors 
Several non-modifiable factors appeared to contribute to 9HPT performance. Most 
notably, the presence of PD appeared to produce higher test times. In fact, people with PD, 
even while on their anti-parkinson medications, generally took approximately 50% longer on 
average than age-matched healthy adults to complete the test. Given that mean 9HPT time in 
the PD sample was approximately 3 SD above the mean time of the healthy comparison group, 
we interpreted the difference to indicate that upper extremity function in the PD sample was 
clearly impaired. The finding further supports the use of the 9HPT as a means of identifying 
upper extremity performance deficits in people with PD [19,20].  Moreover, given that the mean 
9HPT time among H&Y I participants also was one SD above the mean of the healthy 
comparison group and the difference exceeded our calculated MDC value, our data suggested 
that the 9HPT shows promise for detecting decrements in upper extremity function at early 
stages of the disease.   
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In agreement with previous studies involving healthy adults, age was another important 
non-modifiable contributor to 9HPT performance in people with PD. That is, older individuals 
with PD generally took longer to complete the test than younger individuals with PD. 
Importantly, however, we found the relationship between 9HPT performance and age to be not 
as strong in people with PD (r = 0.34 – 0.41) than in healthy adults (r = 0.89 – 0.91) [16]. Based 
on our results, the difference in the strength of the relationship is likely a result of the influence 
of additional factors (i.e., bradykinesia and freezing) that often have a substantial effect on 
people with PD. 
Also consistent with previous studies of healthy adults, our data revealed that women 
with PD performed the 9HPT faster than men with PD of the same age. Importantly, however, 
the influence of gender on 9HPT times in the PD population was relatively small in comparison 
to other factors (i.e., age, bradykinesia, and FOG_Q score). In fact, although statistically 
significant, the mean difference in 9HPT times between men and women with PD was about 4.5 
second (roughly 1/3 of a standard deviation).  Moreover, gender explained only a small 
percentage of the variance of 9HPT times and only for the non-dominant hand. Thus, in our 
view, gender would not be a critical non-modifiable factor to consider when comparing the 9HPT 
time of a person with PD to other people with PD. In contrast, gender would be an important 
consideration when comparing the 9HPT time of a person with PD to a similarly aged healthy 
adult.  
Disease duration and stage of progression also were evaluated as non-modifiable 
factors for their contribution to 9HPT time. Without controlling for other variables, both factors 
were significantly associated with performance; however, neither factor was found to be a 
unique contributor. We suspect that both factors, given their highly significant correlations with 
every other PD-related factor considered, were essentially redundant with the diagnosis of PD 
itself.   
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Influence of Modifiable Factors 
Of several potentially modifiable PD-specific factors, our data revealed that severity of 
bradykinesia contributed most significantly to 9HPT performance. That bradykinesia impairs 
hand dexterity in PD is not new [6]. To our knowledge, however, no previous analysis had 
simultaneously examined the relative contributions of bradykinesia, freezing, tremor, and rigidity 
to physical performance on an upper extremity functional task. The findings suggests that 
compared to the other motor impairments, bradykinesia might make the most suitable target of 
medical, surgical, or rehabilitation interventions designed to improve upper extremity function. 
Further study of this proposition is warranted. 
Compared to the predictable influence of bradykinesia, the significant contribution of 
FOG_Q scores on 9HPT performance was perhaps more surprising. However, the finding was 
in keeping with recent work that suggested upper extremity motor blocks and freezing of gait 
may share a common underlying mechanism [22].  In this context, our data provided further, 
albeit preliminary, support for the idea that interventions targeting motor blocks in PD potentially 
might be useful for improving both lower and upper limb function. 
Tremor and rigidity did not contribute significantly to 9HPT performance. The finding is 
consistent with prior work demonstrating that tremor does not appear to be related to 
bradykinesia3 and that other instrumented measures of bradykinesia such as spiral drawing on a 
digitizing tablet were not influenced by tremor [6].  The finding suggests that interventions 
targeting tremor and rigidity potentially would have less of an impact on upper extremity function 
than those targeting bradykinesia or motor blocks. Further study of this proposition is warranted. 
 
CONCLUSIONS  
The 9HPT appears to be a useful and appropriate measure for assessing upper 
extremity function in individuals with PD.  It is a standardized, ratio scale tool with established 
norms that is commercially available and is portable for use in a variety of settings including the 
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clinic, laboratory, and home. In addition, it assesses a clinical relevant fine motor dexterity task 
that is not examined in the MDS-UPDRS.  Unlike some other commercially available tests [6], 
the 9HPT is relatively inexpensive and requires no specialized training to administer.  
Taken together, our study findings have three broad clinical implications.  First, given 
substantial differences in 9HPT performance between people with PD and healthy adults, a PD-
specific set of typical values appears necessary for performance comparisons among 
individuals with PD. Such comparisons should consider the influence of age but not necessarily 
gender.  Second, given its potential for detecting upper extremity function deficits in early stages 
of PD in comparison to healthy adults, the 9HPT may be an especially important tool for making 
decisions about early intervention that might limit the impact of motor impairment and help 
maintain quality of life. Finally, as a potentially responsive measure of change, the 9HPT should 
be considered as one of a battery of tests for tracking changes in function over time if future 
studies show it has good test-retest reliability when tested one or more weeks apart. 
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Figure 1.   This graph illustrates 9HPT scores for age-matched men and women16, men and 
women with PD, and freezer and non-freezers.  Data are presented separately for the dominant 
and non-dominant hands.  Values are means ± SDs.  Asterisks indicate significant differences 
between conditions at p ≤ 0.003. 
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